Page 10 of 39 · 913 questions tagged clinical-trials.
Details up front: a GLP-1 receptor agonist · 40 °C. I am asking for verification rather than opinion, ideally with something I can read myself. It is possible the…
I have three data points across nine months, which I hope is enough to see a trend. This is presented as though it settles something, and I am not convinced it does.…
I am asking about the protocol logic rather than about my own case specifically. This is presented as though it settles something, and I am not convinced it does. I…
Every comparison I find is either a marketing graphic putting -20.9% next to -14.9% with no caveats, or a methodology piece telling me cross-trial comparison is…
What I have: SUSTAIN-6 · early satiety · 50 mg. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone…
Details up front: SURMOUNT-OSA · hair thinning · 4 mg. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at…
Concretely: early satiety · liraglutide · STEP 1. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a…
My records go back to the first dose with dates, so I can reconstruct the timeline exactly. I would like to know the limits of what can be inferred from this. What I…
The specifics, since they change the answer: 4 mg · semaglutide. I would like to define my thresholds before I have a result, for obvious reasons. I want a plan with…
Numbers first: STEP 2 · 2.5 mg. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to disagree, which…
This is a question about interpretation, not about whether to act — I will take action questions elsewhere. I want the working, not the result — I need to be able to…
The case in front of me: REDEFINE-1 · tirzepatide. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the…
Conditions: ATTAIN-1 · dizziness. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the specifics change…
The case in front of me: nausea · liraglutide · SURMOUNT-1. The figures are clear enough; the question is what they mean and what they do not. I can supply the…
Stated plainly: retatrutide · SURMOUNT-4. I keep seeing this stated as a fact with no explanation attached, and unexplained facts make me suspicious. My background is…
The case in front of me: headache · oral semaglutide · SURPASS-2. The figures are clear enough; the question is what they mean and what they do not. I can supply the…
The case in front of me: SELECT · injection-site erythema. I would like to know the limits of what can be inferred from this. What I am trying to avoid is…
Concretely: REDEFINE-1 · vomiting · 5 mg. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a single…
The label documentation for the agent in question is ambiguous on exactly this point. The figures are clear enough; the question is what they mean and what they do…
Conditions: SURMOUNT-4 · 30 mg. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the specifics change…
The case in front of me: PIONEER-4 · 2 mg. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a single…
The case in front of me: nausea · tirzepatide · SURMOUNT-2. The figures are clear enough; the question is what they mean and what they do not. I can supply the…
The case in front of me: SUSTAIN-6 · oral semaglutide. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if…
This came up because two published schedules for the same agent differ. I would like help reading this properly rather than being told what conclusion to reach. I…